Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.

Trial Details

NCT ID

NCT05896228

Phase

PHASE2

Sponsor

Benjamin T Diamond, MD

Status

RECRUITING

Cancer Type

Relapsed/Refractory Multiple Myeloma

Interventions

Iberdomide
Carfilzomib
Daratumumab
Dexamethasone
Acetaminophen
Diphenhydramine

Locations (sample)

Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

Patients with histologically confirmed MM with progressive disease according to the IMWG criteria 47 during or within 60 days of their last regimen…
Serum monoclonal protein ≥ 1.0 g/dL
Urine monoclonal protein ≥ 200 mg/24 hour
Involved serum immunoglobulin free light chains (FLC) ≥ 10 mg/dL AND abnormal kappa/lambda ratio.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →